Auph short interest.

Aurinia Pharmaceuticals (AUPH) traded ~5% higher pre-market Thursday after the co. raised its outlook and posted better-than-expected Q2 2023 financials. Read more here.

Auph short interest. Things To Know About Auph short interest.

Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Short Interest - MarketWatchE131: 2024 Fantasy President picks, debt ceiling agreement, Dollar dominance & moreWeb29 Sep 2021 ... We follow 790 shorted U.S. domestic biotech stocks with total short interest of $54.5 billion. Short selling in these stocks is highly ...The largest shareholder of Aurinia Pharmaceuticals ( NASDAQ: AUPH) said it plans to withholder support for seven board members at the company's upcoming annual meeting. Iljin SNT, which has a 6.1% ...

1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc.

Mar 23, 2023 · For fiscal 2023, the company expects LUPKYNIS revenue to be between $120 million and $140 million, representing annual growth of 15.4% to 34.6% in terms of net product sales. While analysts expect ... A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short. With the short side of the trade heavily crowded, and a few shares publicly ...

The u/AnalystRipper community on Reddit. Reddit gives you the best of the internet in one place.AUPH Overview Stock Screener Earnings Calendar Sectors Nasdaq | AUPH U.S.: Nasdaq Aurinia Pharmaceuticals Inc. Watch NEW Set a price target alert Open Last Updated: Nov 29, 2023 1:07 p.m. EST...Aurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ...Aurinia Pharmaceuticals (NASDAQ: AUPH) has filed a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Shares are down 12% in ...T2 Biosystems, Inc. Common Stock. $0.2229 +0.002. Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US ...

Feb 28, 2022 · For 2022, Aurinia ( AUPH) projects net revenue from sales of Lupkynis to reach $115M-135M. Several days ago, shares of the company surged in reaction to upbeat remarks made by CEO on its sales ...

Short term price changes are just games with the shorts, they have beat this ... A world energy crisis driving a renewed interest in uranium.

Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.08 beats by $0.11. Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M. Increases 2023 revenue guidance range to $150 - $160 million ...Dec 1, 2023 · The short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 17.19 million shares and it means that shorts have 11.64 day(s) to cover. The consensus price target of analysts on Wall Street is $13.21, which implies an increase of 34.6% to the stock’s current value. 1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc.Mar 2, 2022 · Despite upbeat remarks from its chief executive ahead of the earnings, Aurinia’s (NASDAQ:AUPH) 2022 sales guidance fell short of expectations as net revenue for the year dropped ~9% YoY to $45 ... In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AUPH / Aurinia Pharmaceuticals Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price.

Rumors are that they will pay at least 40 till 44 dollar. Earnings are coming sooner at the 3rd of November. But there is also a high SI. Some buying…In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...Aurinia Pharma ( NASDAQ: AUPH) is scheduled to announce Q3 earnings results on Thursday, November 2nd, before market open. The consensus EPS Estimate is -$0.17 vs -$0.06 in 3Q22 and the consensus ...Short term price changes are just games with the shorts, they have beat this ... A world energy crisis driving a renewed interest in uranium.This page provides short interest, short volume, short volume ratio, short borrow rates, and short squeeze score for the security. US: AUPH / Aurinia Pharmaceuticals Inc - Insider Trading Report This page provides data on the corporate insiders of Aurinia Pharmaceuticals Inc and their trades, trade performance, and predictive analysis. View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Find out why interest in selling AUPH stock has not subsided in some quarters. ... @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 ...AUPH short interest is 8.5%. Also see, Alnylam Pharma is said to be a potential target for Novartis. Recommended For You. Comments (34) Newest. Publish. Have a tip? Submit confidentially to our ...

Aug 2, 2023 · Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus... Aurinia Pharmaceuticals ( NASDAQ: AUPH) rose 5% amid speculation the company may be a takeover target after Tuesday's patent settlement with Sun Pharmaceuticals. Aurinia ( AUPH) surged 38% on ...Nursing is an excellent career path if you’re interested in working in the healthcare industry and strive to provide quality care to patients. If you’re short on time or worry that attending a brick-and-mortar school isn’t possible, one alt...Jan 4, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) rose 5% amid speculation the company may be a takeover target after Tuesday's patent settlement with Sun Pharmaceuticals. Aurinia ( AUPH) surged 38% on ... Short Interest : 17.19M: Short Previous Month : 17.28M: Short % of Shares Out : 11.97%: Short % of Float : 12.21%: Short Ratio (days to cover) 11.64Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ...Meanwhile, Jefferies analyst Maury Raycroft, with a Buy rating on Aurinia ( AUPH ), has cut the per share target to $29 from $34 to imply a premium of ~142% to the last close. Raycroft attributes ...

Live Short Interest data, Utilization, Cost to borrow and much more for Aurinia Pharmaceuticals Inc., Nasdaq:AUPH

Dec 1, 2023 · The short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 17.19 million shares and it means that shorts have 11.64 day(s) to cover. The consensus price target of analysts on Wall Street is $13.21, which implies an increase of 34.6% to the stock’s current value.

Aurinia Pharmaceuticals (AUPH +4.4%) is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release the financials ...Aug 24, 2022 · Approximately 10% of the overall float is currently held short. Two directors bought a collective 10,000 shares in early March. Prior to that several insiders sold just over $1.2 million worth of ... Aurinia Pharmaceuticals (AUPH) traded ~5% higher pre-market Thursday after the co. raised its outlook and posted better-than-expected Q2 2023 financials. Read more here.AUPH / Aurinia Pharmaceuticals Inc short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US:AUPH to the lender of that security. This fee is shown as an annual percentage rate (APR).The u/AnalystRipper community on Reddit. Reddit gives you the best of the internet in one place.Aurinia Pharmaceuticals Stock (NASDAQ:AUPH), Short Interest Report. Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to …Canadian biotech Aurinia Pharmaceuticals (AUPH) lost ~22% pre-market Thursday even after announcing better-than-expected financials for Q3 2022 as the company lowered its full-year...22 votes, 16 comments. 1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc. In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...

Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: P/B: 3.32: EPS next Y: 29.71%: ROA-14.80%: Target Price: 13.21: Perf Year: 76.61%: Cash/sh: 2.35: P/C: 3.85: EPS next 5Y-ROE-18.94%: 52W Range: 4.07 - 12.43: Perf YTD ... Aurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ...Short Interest. Percentage of Shares Shorted 6.91% of the float of ESSA Pharma has been sold short. Short Interest Ratio / Days to Cover ESSA Pharma has a short interest ratio ("days to cover") of 7.8. Change versus previous month Short interest in ESSA Pharma has recently increased by 1.47%, indicating that investor sentiment is …WebShort Interest: 17.28M (10/31/23)Short Interest Change-0.88%: Percent of Float: 13.23%Instagram:https://instagram. beat banksthe trading pit reviewfubo stockssteadily landlord insurance reviews AUPH Overview Stock Screener Earnings Calendar Sectors Nasdaq | AUPH U.S.: Nasdaq Aurinia Pharmaceuticals Inc. Watch NEW Set a price target alert Open Last Updated: Nov 29, 2023 1:07 p.m. EST...As a student, you need to stretch every dollar you have. The good news is there are many banks that help students grow their income by offering high interest rates on their savings. free forex accountkroger walmart 22 votes, 16 comments. 1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc. dgrw stock Frequency Therapeutics (NASDAQ:FREQ – Get Rating) and Appili Therapeutics (OTCMKTS:APLIF – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and …WebAUPH is currently averaging 3,052,205 shares for the last 20 days. Earnings Outlook The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes.